道琼斯工业平均21,917.16-410.32 -1.84%
标普5002,584.59-42.06 -1.60%
纳斯达克7,700.10-74.05 -0.95%
 新闻
BMY or AZN: Which Is the Better Value Stock Right Now?
Zacks · 16小时前
AstraZeneca Announces Lokelma Recommended for Approval in EU for Patients with Hyperkalaemia on Stable Haemodialysis
Benzinga · 1天前
IPO Update: Zentalis Pharmaceuticals Aims For $130 Million IPO
Seeking Alpha - Article · 1天前
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
Zacks · 1天前
The Zacks Analyst Blog Highlights: Apple, Cisco, PepsiCo, AstraZeneca and NextEra
Zacks · 1天前
BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
Business Wire · 1天前
FDA Reports Approved AstraZeneca's Durvalumab In Combo With Etoposide, Either Carboplatin Or Cisplatin
Reuters · 1天前
AstraZeneca Reports Brilinta Reduced Bleeding vs Dual Therapy In High-Risk Coronary Patients In Sub Analyses From Phase 4 TWILIGHT Trial
Benzinga · 1天前
Myriad Genetics seeks expanded use of BRACAnalysis in Japan
Seeking Alpha - Article · 1天前
AstraZeneca's Farxiga successful in late-stage in CKD study
Seeking Alpha - Article · 1天前
AstraZeneca Announces that its IMFINZI Has Been Approved in the US for Extensive-Stage Small Cell Lung Cancer
Benzinga · 1天前
FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease
Business Wire · 1天前
IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
Business Wire · 1天前
AstraZeneca scores win as diabetes drug shown to slow kidney disease
Reuters · 1天前
AstraZeneca Announces Imfinzi Approved in U.S. for Small Cell Lung Cancer
Benzinga · 2天前
AstraZeneca Says Farxiga Phase III DAPA-CKD Trial to be Stopped Early Following Overwhelming Efficacy in Patients with Chronic Kidney Disease
Benzinga · 2天前
Week In Review: Abbisko Raises $70 Million To Develop Cancer Drug Candidates
Seeking Alpha - Article · 2天前
AstraZeneca's lung cancer treatment gets FDA nod
Reuters · 2天前
AstraZeneca: the right prescription
Financial Times · 2天前
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
Benzinga · 2天前